Get the Stockscreener App
45.11
1.61%
-0.74
After Hours:
45.11
Supernus Pharmaceuticals Inc stock is traded at $45.11, with a volume of 495.46K.
It is down -1.61% in the last 24 hours and down -2.36% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
See More
Previous Close:
$45.85
Open:
$45.6
24h Volume:
495.46K
Relative Volume:
0.59
Market Cap:
$2.62B
Revenue:
$776.83M
Net Income/Loss:
$-29.02M
P/E Ratio:
-88.11
EPS:
-0.512
Net Cash Flow:
$82.25M
1W Performance:
-6.55%
1M Performance:
-2.36%
6M Performance:
-15.37%
1Y Performance:
+0.51%
1-Day Range:
$44.81
$45.86
1-Week Range:
$44.81
$49.82
52-Week Range:
$42.45
$59.68
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
45.11 | 2.76B | 776.83M | -29.02M | 82.25M | -0.512 |
TAK
Takeda Pharmaceutical Co Adr
|
18.24 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.16 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.93 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.17 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
512.88 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
A Look at Supernus Pharmaceuticals Inc (SUPN) After 3.4% Decline -- GF Value $43.78 vs Price $45.85 - GuruFocus
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Yahoo Finance
25,400 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Mystic Asset Management Inc. - MarketBeat
Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal - Ad-hoc-news.de
Supernus Pharmaceuticals (SUPN) Stock Looks Reasonable On Sales While Returns Look Strong - Sahm
Britannia, US WorldMeds, Supernus must face US Apokyn antitrust case, plaintiffs say - MLex
Supernus (SUPN) Results Review: The Available Earnings Metric Delivers a Beat in the Latest Reading; After Results: Shares Move 0.35% Lower in the Current UpdateGuidance Revision Trend - vinanet.vn
Supernus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SUPN) - TradingView
Indivior Q2 2026 Earnings Call: Complete Transcript - Sahm
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Sahm
Rice Hall James & Associates LLC Takes $22.80 Million Position in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Bank of America Corp DE - MarketBeat
Details of Bhatt’s PSU Vesting and Tax Withholding at Supernus Pharmaceuticals - Kalkine Media
Supernus Pharmaceuticals CMO Jonathan Rubin Reports Vesting of 750 PSUs and Share Withholding for Taxes - Kalkine Media
Supernus Pharmaceuticals (SUPN) CEO exercises PSUs, withholds shares for taxes - Stock Titan
Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax - Stock Titan
Supernus Pharmaceuticals (SUPN) SVP converts 1,650 PSUs; 797 shares withheld for taxes - Stock Titan
Supernus Pharmaceuticals (SUPN) exec converts 2,500 PSUs, withholds shares for tax - Stock Titan
Supernus Pharmaceuticals, Inc.: Revenue and Earnings Analysts Forecasts Revisions | SUPN | US8684591089 - marketscreener.com
Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals – News - Morgan Lewis
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Why (SUPN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo Finance
Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc. - simplywall.st
Supernus Pharmaceuticals, Inc. (SUPN) Investor Outlook: A 31% Upside Potential Amid Strong Revenue Growth - DirectorsTalk Interviews
Supernus Pharmaceuticals (SUPN) Stock May Be A Bargain After Merger News - Yahoo Finance
Supernus Pharmaceuticals Inc. (S49.SG) Q2 FY2025 earnings call transcript - Yahoo Finance
Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
supernus pharmaceuticals, inc. Positive Earnings Pre-Announcements - RTTNews
Arrowstreet Capital Limited Partnership Trims Holdings in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Hold" at Wall Street Zen - MarketBeat
Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc.,M&A CallSlideshow - Seeking Alpha
Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? - TradingView
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.SUPN - marketscreener.com
New Strong Buy Stocks for August 7th - The Globe and Mail
Best Value Stocks to Buy for August 7th - The Globe and Mail
Millennium group (SUPN) reports Supernus stake falls below 5% ownership - Stock Titan
Rockville-Based Supernus and Indivior Agree to Merge, Creating a $2.2B CNS Powerhouse Headquartered in Maryland - BioBuzz
Rx Rundown: Supernus Pharmaceuticals, TCGX, Sandoz and more - Medical Marketing and Media
Q2 2026 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Supernus And Indivior To Merge And Create $2.2 Billion CNS Biopharmaceutical Company - Pulse 2.0
Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call High - GuruFocus
Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ... - Yahoo! Finance Canada
Supernus Pharmaceuticals (NASDAQ:SUPN) Trading Down 6%Here's Why - MarketBeat
Supernus Pharmaceuticals Falls as Investors Weigh Newly Announced Indivior Merger Terms - moomoo.com
Supernus Pharmaceuticals falls as investors weigh newly announced Indivior merger terms - Quiver Quantitative
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Supernus and Indivior to Merge, Creating Diversified CNS Biopharma Company - Contract Pharma
$1.8bn merger unites Supernus and Indivior in CNS therapeutics play - BioXconomy
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook - Yahoo Finance
Supernus and Indivior merge to create scaled, CNS-focused entity - Yahoo Finance
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Supernus Pharmaceuticals Inc Stock (SUPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rubin Jonathan | SVP, Chief Medical Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
750 |
0 |
14,342 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Aug 12 '26 |
Option Exercise |
0.00 |
2,500 |
0 |
19,795 |
| Mottola Frank | SVP, Chief Tech. Ops. Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
1,650 |
0 |
20,341 |
| DEC TIMOTHY C | Senior Vice-President & CFO |
Aug 12 '26 |
Option Exercise |
0.00 |
1,250 |
0 |
9,733 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Option Exercise |
38.51 |
50,000 |
1,925,537 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Option Exercise |
33.62 |
50,000 |
1,681,205 |
67,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Option Exercise |
39.40 |
7,250 |
285,650 |
24,294 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 17 '26 |
Sale |
50.30 |
50,000 |
2,514,886 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 16 '26 |
Sale |
50.28 |
50,000 |
2,513,925 |
17,044 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO |
Mar 18 '26 |
Sale |
49.60 |
7,250 |
359,621 |
17,044 |
1.12%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):